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Summary The effects of cell density on drug-induced cell kill kinetics were studied by means of clonogenic
assay using 3 human leukaemia-lymphoma cell lines. Mitoxantrone, daunorubicin, doxorubicin, vincristine
and bleomycin were progressively less efficacious when cell density increased (positive inoculum effects),
whereas the effects of cis-platin and carboplatin were not influenced by cell density. Inoculum effects were
related to the kind of chemotherapeutic agents tested, irrespective of the type of cell lines used. Preincubation
of mitoxantrone or doxorubicin in the presence of cells in high density resulted in decreases in the cytocidal
activity, whereas the effects of bleomycin, vincristine and cis-platin were unaffected. These results show that
cell density affects the biological effect of certain chemotherapeutic agents. Inactivation of drugs by high
densities ofcells partially explains this phenomenon.
For many years the relationship between tumour
size and sensitivity to anticancer agents affected
chemotherapeutic strategies (Skipper & Schabel,
1982). Clinical experience suggests that patients
with high tumour load are less amenable to
treatment. High leukocyte counts in patients with
ALL and AML are usually considered a poor
prognostic sign in terms of remission induction
(Crowther et al., 1975; Robinson et al., 1980;
Simone et al., 1975), remission duration (Hug et al.,
1983; Robinson et al., 1980; Schauer et al., 1983)
and survival (Freireich et al., 1961; George et al.,
1973; Simone et al., 1975). Leukapheresis prior to
chemotherapy resulted in an improved rate of
remission (Cuttner et al., 1983). These reports
suggest that not only the total tumour load, but cell
density per se is an important factor for
chemotherapeutic efficacy. We studied the effects of
cell density on drug-induced cell kill kinetics in
vitro.
Materials and methods
Cell lines
The DND-39A Burkitt lymphoma cell line was
derived from the pleural effusion of a man with
American Burkitt lymphoma (Ohnuma et al., 1980).
The MOLT-3 T-lymphocyte leukaemia line was
established from a patient with ALL (Minowada et
al., 1972). The HL-60 acute promyelocytic
leukaemia cell line (Gallagher et al., 1979) was a
gift from Dr. Ruscetti of the National Cancer
Institute, Bethesda, MD. These cell lines were
maintained in our laboratory as a suspension in
culture flasks containing RPMI-1640 medium
(GIBCO, Grand Island, NY) containing 10% (v/v)
heat-inactivated FBS (GIBCO, Grand Island, NY)
and fed 3 times per week with fresh medium.
Chemotherapeutic agents
The following drugs were tested: bleomycin sulfate
(Bristol Laboratories, Syracuse, NY); carboplatin
(supplied by the National Cancer Institute,
Bethesda, MD); cis-platin (Bristol Laboratories);
daunorubicin hydrochloride (supplied by the
National Cancer Institute, Bethesda, MD);
doxorubicin hydrochloride (Adria Laboratories,
Columbus, OH); mitoxantrone hydrochloride
(Lederle Laboratories Division, American
Cyanamide, Pearl River, NY) and vincristin sulfate
(Eli Lilly Laboratories, Indianapolis, IN).
Drug powders were reconstituted initially
according to the accompanying instructions and
further dilutions in PBS. The drug dilutions were
'freshly prepared for each experiment.
Determination ofdrug-induced cell kill kinetics
Exponentially growing cells (2-10 x 105 viable
cellsml-1) were diluted or concentrated to different
cell densities ranging from 102 to 108 viable
cellsml-1 in fresh RPMI-1640 medium containing
10% FBS in either 15ml culture tubes (Falcon No.
3033) or 50ml centrifuge tubes (Falcon No. 2098).
The cells were exposed to graded concentrations of
each drug for 1 h at 37°C in humidified 5%
C02/95% air. Drug exposure was carried out in a
total volume ranging from 1 ml (108 cells) to 200ml
(102 cellsml-1). At the end of the incubation
period the cells were washed twice with medium
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and cell densities were adjusted to 3 x 104 cellsml-1
for DND-39A and 5 x104 cellsml-1 for MOLT-3
and HL-60 cells. Aliquots (100pl) of cell suspension
were plated on 0.5% agar (Noble agar, Difco,
Detroit, MI) replica plate (60 x 15mm, Corning,
NY) containing RPMI-1640 medium and 10% FBS
(Koroki, 1970). Colonies (more than 40 cell
aggregates) were enumerated and the survival
fraction was determined. In this system the number
of colonies developed is proportional to the number
of cells plated. When colonies number more than
2,000-3,000/plate, however, they conglomerate,
thus, making it difficult to count them accurately.
The plating efficiency of DND-39A cells was 30-
40%, and that of MOLT-3 and HL-60 cells, 10-
20%. The plating efficiency was unchanged after
1 h of incubation in control cells with no drug
within a range of cell densities studied. Each
experiment was done in triplicate and repeated at
least twice.
Inactivation studies
For inactivation studies each drug at a
concentration equivalent to 10 times the LD30_50
for 104 viable DND-39A cellsml- was pre-
incubated in the medium alone, in the medium
containing 104 cellsml -1 or 108 cellsml -1 for lh at
37°C in a humidified 5% C02/95% air incubator.
The cells were centrifuged and the supernatant was
separated. The 300,1 aliquots of supernatant were
added to 3ml of cell suspension containing 104
DND-39A cellsml1 for 1 h. The cells were then
washed free of drug and the cell kill effects were
determined by clonogenic assay. Drugs with no
preincubation were also included as controls.
Results
The influence of cell density on the drug
concentration-cell lethality curves (dose-response
curves) for 7 diverse chemotherapeutic agents is
shown in Figure 1. As the DND-39A cell density
increased, the efficacy of mitoxantrone, doxo-
rubicin, daunorubicin, bleomycin and vincristine
progressively decreased and the dose-response curve
moved to the right. This decrease in efficacy was
most pronounced with mitoxantrone (Figure IF).
Thus, the LD50 of mitoxantrone was 1.4, 1.8, 6.0
and 126-fold higher when the cell density increased
from 102 to 104, 106, 107 and 108 cellsmlP-. When
cell density increased from 104 and 108 cellsml-
the changes in LD50 were in decreasing order,
30-fold for daunorubicin, 27-fold for
doxorubicin, 15-fold for vincristine and 9-fold for
bleomycin. In contrast, the cell kill effects of cis-
platin and carboplatin were independent of cell
density and the dose-response curves for each cell
density studied overlapped one another (Figure lB
and IC). The influence of cell density on the cell
kill effects of certain chemotherapeutic agents is
similar to the effect of the size of microbial
inoculum in vitro for certain antimicrobial agents
(see Discussion) and thus can be termed 'inoculum
effect'.
In order to examine whether the inoculum effect
described above in certain chemotherapeutic agents
seen with the DND-39A cell line was specific for
this particular cell line we tested the effect of cell
density using 2 other cell lines, MOLT-3 and HL-
60, and the results were compared between
mitoxantrone and cis-platin (Figure 2).
Mitoxantrone, again, showed positive inoculum
effect for these 2 cell lines and the dose-response
curves for all 3 cell lines moved to the right when
the cell density increased from 104 to 108
cellsml-1. In contrast, for all the 3 cell lines tested,
cis-platin showed a lack of inoculum effect and
there was no shift of the dose-response curves
whether the cell density was 104 cellsml- or 108
cellsml-1.
One plausible explanation for the positive
inoculum effect is the progressive inactivation of
the cytocidal effect of these chemotherapeutic
agents by the tumour cells. In order to test this
hypothesis, the effect was evaluated after
preincubation of the drugs with 108 DND-39A
cellsml-l and the results are shown in Figure 3.
Preincubation of mitoxantrone and doxorubicin
with the high density of cells resulted in substantial
decreases in activity, whereas the efficacy of
bleomycin, vincristine and cis-platin were
unaffected.
Discussion
The present study clearly establishes cell density as
an important factor in the biological activity of
certain chemotherapeutic agents. In the realm of
antimicrobial antibiotics this phenomenon is known
as the inoculum effect; increases in the inoculum
size of certain microbial organisms produce
decreases in the area of antimicrobial effects
(Basker et al., 1979; Bodey & Pan, 1977).
The degree of inoculum effect was variable for
different chemotherapeutic agents tested. Thus, by
comparing the ratio of LD50 at 108 cellsml-1 over
that at 104 cellsml-l the inoculum effect was most
pronounced with mitoxantrone, followed, in the
decreasing order, by daunorubicin, doxorubicin,
vincristine, bleomycin, cis-platin and carboplatin.
In using 3 different cell lines we have demonstrated
that the inoculum effect is not related to the type of
cells tested, but to the kind ofdrugs used.B
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Figure 1 The influence of cell density on drug concentration-cell lethality. curve. DND-39A Burkitt
lymphoma cells at different cell densities were exposed to various chemotherapeutic agents for 1 h, washed
free of drug and cell lethality was determined by clonogenic assay. The numbers next to each curve indicate
cell density (number of cellsml-l of culture medium). Each data point represents a mean of at least 6
experimental values. All experimental values were within 50% of the mean.
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Figure 2 The influence of cell density on drug concentration-cell lethality curve as studied in 3 different cell
lines. (0), data with 104 cellsml-1; (A), 108 cellsml-1. Each data point represents a mean of at least 6
experimental values. All experimental values were within 50% of the mean.
We studied antibiotics (bleomycin, daunorubicin
and doxorubicin); synthetic aminoanthraquinones
(mitoxantrone); vinca alkaloids (vincristine) and
platinum containing compounds (cis-platin and
carboplatin). The mechanisms of action included
scission of DNA (bleomycin), intercalation with
DNA (daunorubicin, doxorubicin, mitoxantrone
and platinum analogues) and tubulin toxins
(vincristine) (Calabresi & Parks, 1985). The
observation of inoculum effects in diverse chemo-
therapeutic agents in terms of chemical structure
and mechanism of action indicates that this
phenomenon is common among clinically active
chemotherapeutic agents.
We did not test anti-metabolites because a
preliminary study showed that 5-fluorouracil was
not active against DND-39A cells in 1 h exposure
experiments, up to 1 x 103 M concentrations.
Cytosine arabinoside also required more than 1 h of
drug exposure to be active. Similarly, we were
unable to evaluate melphalan, an alkylating agent,
mainly because of its instability in solution.
The mechanism of the inoculum effect produced
by certain anticancer agents is unclear. The
preincubation studies have only partially explained
this phenomenon. Preincubation studies should be
positive if drugs are either inactivated by or
absorbed into the cells. If drugs are simply
adsorbed into the cells they should exert the same
degree of lethal effect, irrespective of cell density.
Since this was not the case for mitoxantrone and
doxorubicin (Figure 1) it is more likely that the
drugs were inactivated during the preincubation
period.
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Figure 3 Effects of preincubation of chemotherapeutic agents on DND-39A cell lethality. Each drug at a
concentration equivalent to 10 times the LD30 50 for 104 cells ml- cell density was preincubated for h in
the medium alone (bar B), in the culture medium containing 104 cellsml- (bar C) and in the culture medium
containing 108 cellsml - (bar D). The supernatant was separated and its cell kill effect was evaluated by
adding in a new tube containing DND-39A cells. Bar A indicates the efficacy of each drug freshly prepared
and evaluated in the same manner. Error bars, s.d.
This interpretation is reminescent of that seen
with certain antimicrobial agents. For example,
ureidopenicillins' inhibitory concentrations in vitro
were shown to be influenced by the size of the
inoculum of Klebsiella aerogenes and Pseudomonas
aeruginosa, and this phenomenon was reported to
correlate with the degree of inactivation of
ureidopenicillins by ,B-lactamases from these micro-
organisms (Basker et al., 1979).
Inactivation (or adsorption) of chemotherapeutic
agents by tumour cells could not explain the total
phenomenon, however. Thus, bleomycin and
vincristine, both of which showed a positive
inoculum effect, were not influenced by
preincubation with the cells. In these cases the
following alternative explanations can be offered:
First, concentrations needed for the dose-
response curve for those with positive inoculum
effects, were, in general, lower than cis-platin and
carboplatin on a molar basis. It is conceivable,
therefore, that there was not enough drug available
to the receptor or binding sites of all the cells when
high cell densities were used, which might have
resulted in more cells remaining unaffected. Since
platinum analogues and anthracycline antibiotics
are known to intercalate with DNA, DNA is
probably the major binding site for these
compounds. They also bind with cell membrane
components and certain anthracycline compounds
with cytoplasmic components (Young et al., 1981).
Tubulin proteins are known to be specific receptors
for vinca alkaloids (Totsuka et al., 1982; Wilson et
al., 1974).
Second, it is possible that in the cases of
bleomycin and vincristine, cells are not uniformly
sensitive to these agents and that a large inoculum
size might have included more cells that are
inherently resistant to these agents. Less steep dose-
response curves for bleomycin and vincristine
suggest that this alternative mechanism exists. Such
an explanation has been advanced for the inoculum
effect observed with mezlocillin (Bodey & Pan,
1977).
The present study shows that the relationship
between the size of microbial inoculum and the
efficacy of antimicrobial antibiotics seems to exist
for the size of tumour cell concentrations and the
biological effects of certain anticancer agents. It is
uncertain at this time whether the lack of inoculum
effect seen with cis-platin and carboplatin is specific
for platinum analogues or for other agents with
similar mechanisms of action, including alkylating
agents.
Our observation may have a bearing in several
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important areas of cellular pharmacology. First,
human tumour clonogenic assays are reported to be
useful in predicting response (Salmon et al., 1978;
von Hoff et al., 1981). In such an assay usually 105
cellsml- I are exposed to anticancer agents.
Observations made in this study suggests that 105
cells used in in vitro assay may not represent the
circumstances in vivo for certain drugs and may
over-predict for positive effects. Second, it seems
probable that drugs with high inoculum effects
(e.g., mitoxantrone and daunorubicin) are those-
with lesser activity against solid tumours.
Determination of inoculum effects may be useful in
deciding which drugs are therapeutically active for
patients with solid tumours. Third, the present
study indicating that certain drugs are less
efficacious at high tumour cell densities may partly
be a reflection of known in vivo drug effects, in that
chemotherapeutic agents are often more active for
micrometastatic diseases, than bulky disease.
Finally, the lack of inoculum effect of cis-platin
and carboplatin seems consistent with their
usefulness in the treatment of patients with solid
tumours. This observation has now been extended
to studies involving multicellular tumour spheroids
(Inoue et al., 1985).
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